Abstracts tagged "methotrexate (MTX) and pharmacokinetics"

Abstract Number: 601 • 2016 ACR/ARHP Annual Meeting
Differing Contribution of Methotrexate Polyglutamation to Infliximab and Adalimumab Exposure As Compared to Etanercept
Thierry Dervieux¹, Joel M. Kremer², Tyler O'Malley¹, Alan J Kivitz³, John Conklin⁴ and Michael Weinblatt⁵, ¹Research and Development, Exagen Diagnostics, Vista, CA, ²Albany Medical College, Albany, NY, ³Altoona Arthritis & Osteo Ctr, Duncansville, PA, ⁴1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁵Division of Rheumatology, Immunology and Allergy, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Methotrexate (MTX) is known to improve exposure and clinical outcome to anti-tumor necrosis factor (TNF) therapy. While the precise mechanism of action for the…
Abstract Number: 1652 • 2015 ACR/ARHP Annual Meeting
A HPLC-SRM-MS Based Method for the Detection of Adherence to Low-Dose Oral Methotrexate
James Bluett¹, Thierry Wendling², Kayode Ogungbenro², Isabel Riba-Garcia³, Richard Unwin³, Suzanne M. Verstappen⁴ and Anne Barton^5,6, ¹Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, ²Centre for Applied Pharmacokinetic Research, Manchester Pharmacy School, The University of Manchester, Manchester, United Kingdom, ³Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom
Background/Purpose: Whilst methotrexate (MTX) is the first-line treatment of rheumatoid arthritis (RA), response is not universal. Rates of adherence reported in the literature range from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].